http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170017522-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_665a1ccbeb11cc1bcdd3c4d078d4e3f0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1213 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-12 |
| filingDate | 2015-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcd297cf5420e6ff202cf5ac66512e8b |
| publicationDate | 2017-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170017522-A |
| titleOfInvention | Chitosan-chelator hydrogel for treating cancer and method to prepare the same, and pharmaceutical composition and embolotherapy composition comprising the same |
| abstract | The present invention relates to a radioactive or non-radioactive chitosan-chelator hydrogel and a method for preparing the same, and a composition for cancer treatment and embolization comprising the same as an active ingredient. The chitosan-chelator hydrogel according to the present invention is prepared to have a size of 100-300 m and blocks blood flow toward a tumor tissue to interrupt supply of oxygen and nutrients to the tumor cells, and thus can be used for embolization treatment for cancer tissues. Particularly, a radionuclide-labeled chitosan-chelator hydrogel directly labels a radionuclide or supports a drug upon formation of a hydrogel, and thus has excellent radionuclide labeling efficiency and labeling stability to minimize a free radionuclide. Therefore, a treatment effect of the radionuclide and that of the drug can be expected at the same time, thereby increasing a treatment effect at a focus. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021153823-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180046559-A |
| priorityDate | 2015-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.